Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02564198 · ClinicalTrials.gov registry record · Phase 1
A Study of Ramucirumab (LY3009806) in Children With Refractory Solid Tumors
A Phase 1 study of Pediatric Solid Tumor and Recurrent Tumor, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 29
- Enrollment target
- 20
- Study locations
NCT02564198 is a Phase 1 study of Pediatric Solid Tumor and Recurrent Tumor that has completed, run by Eli Lilly and Company. The registered enrollment target is 29 participants, below the 1,130-participant average among 10 other Pediatric Solid Tumor trials with a reported enrollment target (97% lower). The trial reports 20 study locations across 17 states.
The verdict
NCT02564198, a Phase 1 study of Pediatric Solid Tumor and Recurrent Tumor, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 29 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main purpose of this study is to evaluate the safety of the study drug known as ramucirumab in children with recurrent or refractory solid tumors including central nervous system (CNS) tumors.
Conditions Studied
Interventions
- DRUG Ramucirumab
Study Locations (20)
California
- Children's Oncology Group - Monrovia
- Childrens Hospital of Orange County - Orange
- University of California, San Francisco - San Francisco
Pennsylvania
- Children's Hospital of Philadelphia - Philadelphia
- Childrens Hospital of Pittsburgh - Pittsburgh
Alabama
- Childrens Hospital of Alabama - Birmingham
District of Columbia
- Children's National Medical Center - Washington D.C.
Georgia
- Children's Healthcare of Atlanta at Scottish Rite - Atlanta
Illinois
- Ann & Robert H Lurie Children's Hospital of Chicago - Chicago
Indiana
- Riley Hospital for Children - Indianapolis
Maryland
- Mark O Harfield-Warren Grant Magnuson Clinical Center - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2015-12-11 |
| Est. Completion | 2019-07-16 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02564198
The ClinicalTrials.gov registry entry for NCT02564198 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,130-participant average among 10 other Pediatric Solid Tumor trials with a reported enrollment target (97% lower). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Pediatric Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which Ramucirumab is the first listed.
NCT02564198 reports 20 study locations spanning 17 distinct geographic areas - top geographies include California, Pennsylvania, Alabama.
Frequently Asked Questions
What is clinical trial NCT02564198 about?
NCT02564198 is a clinical study titled "A Study of Ramucirumab (LY3009806) in Children With Refractory Solid Tumors". The main purpose of this study is to evaluate the safety of the study drug known as ramucirumab in children with recurrent or refractory solid tumors including central nervous system (CNS) tumors.
What is the current status of trial NCT02564198?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 29 participants. The study started on 2015-12-11. Estimated completion is 2019-07-16.
What conditions does trial NCT02564198 study?
This clinical trial studies the following conditions: Pediatric Solid Tumor, Recurrent Tumor, Refractory Tumor, CNS Malignancies.
What interventions are being tested in trial NCT02564198?
The interventions under investigation include: Ramucirumab (DRUG).
Who is sponsoring clinical trial NCT02564198?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02564198 being conducted?
This trial has 20 study locations across Alabama, California, District of Columbia, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pediatric Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
RECRUITING · Phase 1
-
Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients
RECRUITING · Phase 1
-
Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
RECRUITING · Phase 1
-
Targeting Pediatric Brain Tumors and Relapsed/Refractory Solid Tumors With Sodium Glucose Cotransporter 2 Inhibitors (SGLT2i)
RECRUITING · Phase 1
-
B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults
ACTIVE NOT RECRUITING · Phase 1
-
Dose Escalation Study of CLR 131 in Pediatric Relapsed/Refractory Malignant Tumors Including Neuroblastoma and Sarcomas
ACTIVE NOT RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.